Cost-effectiveness of deucravacitinib versus apremilast of moderate-to-severe plaque psoriasis in China
Abstract Objectives The study aimed to assess the cost-effectiveness of deucravacitinib versus apremilast for treating moderate-to-severe plaque psoriasis from the Chinese healthcare system’s perspective. Methods The treatment efficacy of deucravacitinib was compared with apremilast using response r...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2025-09-01
|
| Edice: | BMC Health Services Research |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s12913-025-13403-3 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|